COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #28 of 63
11/13 Late treatment study
Elgazzar et al., Research Square, doi:10.21203/ (Preprint)
Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Source   PDF   Share   Tweet
RCT comparing ivermectin + SOC vs. HCQ + SOC, showing a significant reduction in mortality with ivermectin. Mortality relative risk:
RR 0.11, p = 0.12 (mild/moderate cases)
RR 0.1, p < 0.001 (severe cases)
The HCQ dose is relatively low and may be too low to reach therapeutic levels. This paper also reports a prophylaxis study [1].

Elgazzar et al., 11/13/2020, Randomized Controlled Trial, Egypt, Africa, preprint, 6 authors, dosage 400μg/kg days 1-4.
risk of death, 91.7% lower, RR 0.08, p < 0.001, treatment 2 of 200 (1.0%), control 24 of 200 (12.0%).
risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 100 (0.0%), control 4 of 100 (4.0%), mild/moderate COVID-19.
risk of death, 90.0% lower, RR 0.10, p < 0.001, treatment 2 of 100 (2.0%), control 20 of 100 (20.0%), severe COVID-19.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.